Wellcome Trust-Medical Research Council Cambridge Stem Cell Institute, Clifford Allbutt Building, Cambridge Biomedical Campus, University of Cambridge, Cambridge CB2 0AH, UK.
MRC Centre for Regenerative Medicine, Edinburgh bioQuarter, University of Edinburgh, Edinburgh, EH16 4UU, UK.
Nat Rev Neurosci. 2017 Nov 16;18(12):753-769. doi: 10.1038/nrn.2017.136.
Although the core concept of remyelination - based on the activation, migration, proliferation and differentiation of CNS progenitors - has not changed over the past 20 years, our understanding of the detailed mechanisms that underlie this process has developed considerably. We can now decorate the central events of remyelination with a host of pathways, molecules, mediators and cells, revealing a complex and precisely orchestrated process. These advances have led to recent drug-based and cell-based clinical trials for myelin diseases and have opened up hitherto unrecognized opportunities for drug-based approaches to therapeutically enhance remyelination.
尽管过去 20 年来基于中枢神经系统祖细胞的激活、迁移、增殖和分化的髓鞘修复这一核心概念没有改变,但我们对这一过程背后的详细机制的理解已经有了相当大的发展。现在,我们可以用一系列的途径、分子、介质和细胞来装饰髓鞘修复的中心事件,揭示出一个复杂而精确协调的过程。这些进展导致了最近针对髓鞘疾病的基于药物和细胞的临床试验,并为基于药物的方法提供了以前未被认识到的治疗性增强髓鞘修复的机会。